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The use of prophylactic antibiotics has been nowadays
generally accepted as an important precaution to prevent
infectious complications following surgery. Surgeons may
sometimes lack the required infectiological knowledge, and
to keep an up-dated overview of the extensive literature
remains difficult, hence we have to rely on meta-analysis
and to benefit from collating information from different
meta-analysis [1]. In this article, Woodfield et al. have
shown with their meticulously performed meta-analysis of
90 publications that ceftriaxone is more effective than most
other prophylactic antibiotics to reduce surgical site
infections, urinary tract infections and postoperative
pneumonia in patients at risk [2].
Ceftriaxone is a third generation cephalosporin that
covers a wide range of gram negative and gram positive
bacteria. It has bactericidal effects by inhibiting the syn-
thesis of the cell wall. Ceftriaxone has a high stability
against the vast majority of beta-lactamases (i.e. penicil-
linases and cephalorsporinases), which remained unchan-
ged during the last 40 years. Already 30 min after
intravenous injection, serum levels far above the minimal
inhibitory concentration (MIC) for most organisms are
achieved. Due its excellent penetration into different tis-
sues and fluids (e.g. bone, lung, liver, heart, skin, bile,
cerebrovascular fluid) as well as the prolonged half-life of
8 h, a sustained concentration well above the MIC for most
bacteria has been observed for 24 h after single-shot
application.
The chemical and pharmacokinetical properties of cef-
triaxone have contributed to the rather unique clinical
characteristics, which almost fulfil every criteria for an
‘‘ideal’’ prophylactic antibiotics. First, despite ceftriaxone
is widely used for more than four decades, no relevant
resistance formation could have been observed. Second,
the capacity to nearly penetrate in every tissue and fluid
compartment, and the long half-life of 8 h provide a high
ceftriaxone concentration with a long-lasting protective
effect. Thus, ceftriaxone successfully prevents both, sur-
gical site infections (local action) and remote infections,
away from the surgical site (systemic action). Not sur-
prisingly, it reveals its best effects for clean-contaminated
and contaminated surgical interventions. Third, since gen-
eric products are now available, cost for ceftriaxone has
been decreased in many countries.
The main goal of prophylactic antibiotics in surgery is
still to prevent infections directly related to the interven-
tion, e.g. surgical site infections, but also remote infectious
complications, e.g. respiratory tract in case of abdominal
surgery [3]. In order to achieve those goals, a responsible
use of antibiotics is pivotal to achieve low infection rates,
to prevent resistance formation, and to keep a good cost-
effectiveness. There is a broad range of antibiotics that are
available for prophylaxis. Numerous antibiotic regimens
have been proposed for many different indications and
surgical specialities, respectively. Surgeon’s choice for one
particular antibiotic is influenced by various factors.
Among those, institutional traditions, personal experience,
and last but not least, strong economical interests of the
pharmaceutical industry often play a key role, while evi-
dence is often of subordinate importance.
We should keep in mind that the number of newly released
antimicrobial drugs has steadily decreased over the last
30 years, while the number of multiresistant organisms has
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rapidly increased (e.g. MRSA, ESBL bacteria). Therefore, a
careful selection of the respective antibiotics for prophylaxis
is of utmost importance. The pharmaceutical companies may
suggest new antibiotics with ‘‘better’’ mode of actions,
although there is no real need to change current antibiotic
prophylaxis. Epidemiological aspects weigh harder in this
setting than individual considerations. According to this
meta-analysis, ceftriaxone has kept its excellent profile, and
its use is still safe and effective.
Despite all the beneficial effects, we should not forget
that prevention of infectious complications related to sur-
gery is not solely based on antibiotic prophylaxis. Local
bacterial contamination and systemic spillage are also
dependent on the surgical technique. Prevention of inad-
vertent opening of the respiratory, gastrointestinal and
genitourinary tract, minimizing blood loss, preoperative
correction of malnutrition and other co-morbidities remain
crucial.
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